论文部分内容阅读
目的 :评价153Sm EDTMP对多发性骨转移癌的止痛效果及消退作用。方法 :首次静脉给药剂量为 37MBq/kg。重复治疗剂量 ,结合患者病情、病灶数、血象等酌情增减。 3次为一个疗程 ,给药间隔平均 6周。结果 :15 6例骨转移患者 ,骨痛完全缓解 5 2例 (33 3% ) ,部分缓解 81例 (5 1 9% ) ,无效 2 3例 (2 1 2 % )。止痛有效率为 85 2 %(133/ 15 6 ) ,72例骨转移患者治疗后 ,病灶骨 /全身骨放射性计数率下降 5 0 %以上 14例 (19 4% )。下降 2 5 %以上 2 1例 (2 9 2 )、转移灶消退总有效率为 48 6 %。结论 :153Sm EDTMP不仅止痛效果非常显著 ,而且对转移灶有一定的消退作用
Objective : To evaluate the analgesic effect and extinction of 153Sm EDTMP on multiple metastatic bone cancers. Method: The first intravenous dose of 37MBq/kg. Repeat treatment doses, combined with the patient’s condition, number of lesions, blood, etc., as appropriate, increase or decrease. 3 times for a course of treatment, the average interval of 6 weeks. RESULTS: In 156 patients with bone metastases, bone pain was completely relieved in 52 patients (33 3%), partly relieved in 81 patients (51.9%), and invalid in 23 patients (221%). The effective rate of analgesia was 85 2% (133/15 6 ). After treatment of 72 patients with bone metastases, the bone/systemic bone count rate decreased by more than 50% in 14 cases (19.4%). The total effective rate of metastases remission was 48.6% in 25% cases (29.2%). Conclusion: The 153Sm EDTMP not only has a very significant analgesic effect, but also has a certain regressive effect on the metastasis.